BioMarin Pharmaceuticals BMRN EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from BioMarin Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's EBITDA margin?
- BioMarin Pharmaceuticals (BMRN) reported EBITDA margin of 13.5% in Q1 2026.
- How has BioMarin Pharmaceuticals's EBITDA margin changed year-over-year?
- BioMarin Pharmaceuticals's EBITDA margin decreased by 44.1% year-over-year, from 24.1% to 13.5%.
- What is the long-term trend for BioMarin Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's EBITDA margin has grown at a 38.1% compound annual growth rate (CAGR), from 3.3% to 16.7%.
- What does EBITDA margin mean?
- Operating cash profitability per sales dollar, before interest, taxes, and non-cash charges.
- How do you interpret EBITDA margin?
- Useful for comparing operating profitability across firms with different depreciation policies and leverage. High EBITDA margin alongside heavy capex can still mean weak free cash flow — pair it with FCF margin.
- How does EBITDA margin compare across companies?
- Widely used to compare capital-intensive businesses on a like-for-like basis. Less meaningful for banks and insurers.